Corporate announcement: COVID-19 update
Neuraxpharm informs that our manufacturing plant Inke in Barcelona is fully operational.
In light of the novel coronavirus (COVID-19) pandemic, as a pharmaceutical company present in 12 European countries, it is a Neuraxpharm priority and responsibility to protect the wellbeing and safety of our employees.
At the same time, we have the fundamental role in regard to the community and the healthcare industry to guarantee the supply of medicines addressed to patients.
We will continue serving our customers by working remotely where possible, while ensuring a continuous manufacturing of our products highly prioritizing health and safety measures for our employees at our facilities.
Special recognition goes to all our professionals who continue working on-site for their exceptional commitment in order to continue serving our customers in the pharmaceutical industry in the best way possible.
We are proud of the strong dedication of our production teams to continue this vital work.
As an essential service during the coronavirus pandemic, all of us at Inke and Neuraxpharm are committed to safeguard the supply of active pharmaceutical ingredients and medicines to our communities.
At Inke, we are taking the necessary precautions, and we are monitoring the situation closely as it develops.